Molecular profiling of tumor tissue using targeted clinical proteomics

使用靶向临床蛋白质组学对肿瘤组织进行分子分析

• 批准号: 8349470
• 负责人: Donald Johann
• 金额: $ 10.19万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8349470
• 关键词: Biological Markers; Blood; Cancer Biology; Cancer Patient; Clinical; Clinical Trials; Complex; Diagnosis; Drug Delivery Systems; Economic Burden; Freezing; Goals; Immunoassay; Immunohistochemistry; Individual; Investigation; Malignant Neoplasms; Maps; Medical Economics; Molecular Profiling; Newly Diagnosed; Normal tissue morphology; Organ; Patients; Proteins; Proteome; Proteomics; Research; Solid; Solid Neoplasm; Techniques; Testing; Time; Tissues; Toxic effect; Treatment Efficacy; Tumor Tissue; cohort; evidence base; insight; molecular phenotype; novel strategies; tool; tumor

Our results have shown the ability to detect tumor residing proteins in the blood of a patient with a newly diagnosed non-metastatic cancer. In depth proteomic profiling of an individual patient's tumor for further elucidation of the particular molecular phenotype. A panel of putative markers are under investigation with high throughput techniques employing suitable immunoassays to test for general applicability to a much larger patient cohorts with this particular solid organ tumor. Such an approach facilitates maximization of therapeutic efficacy, minization of toxicities, and an attempt to reduce medical economic burdens. Further studies have now shown that a thin-tissue approach utilizing patient tumors, provide a discovery platform for key proteins involved in the individual patient's cancer. Many of these are drug targets. This new approach is nearly identical to the tissue and time requirements of IHC (immunohistochemistry), but is complementary. A major goal is to provide a new research tool for clinical trials, using this practical approach of molecular profiling on a protein level, with thin tissue sections from the patient's actual tumor.

我们的结果表明，有能力检测新诊断为非转移性癌症患者血液中蛋白质的肿瘤。深度对个体患者肿瘤的蛋白质组学分析，以进一步阐明特定的分子表型。一系列推定的标记正在研究，使用合适的免疫测定法进行高通量技术，以测试与这种特定的固体器官肿瘤对更大的患者同伙的一般适用性。这种方法促进了治疗功效的最大化，毒性的降低以及减轻医疗经济负担的尝试。现在，进一步的研究表明，使用患者肿瘤的薄组织方法为参与个体患者癌症的关键蛋白提供了发现平台。其中许多是药物靶标。这种新方法几乎与IHC（免疫组织化学）的组织和时间要求相同，但是互补的。一个主要目标是使用这种实际的分子分析方法在蛋白质水平上提供一种新的研究工具，并在患者的实际肿瘤中提供薄的组织切片。